Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer

Oliver Sartor, MD
Published: Wednesday, Aug 09, 2017



Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Cellular studies are still needed to investigate the immune response caused by sipuleucel-T, explains Sartor.

Additionally, studies are needed to determine if immunotherapies are more active in different patient populations, states Sartor.
 


Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Cellular studies are still needed to investigate the immune response caused by sipuleucel-T, explains Sartor.

Additionally, studies are needed to determine if immunotherapies are more active in different patient populations, states Sartor.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x